04:03 AM EDT, 04/05/2024 (MT Newswires) -- Contineum Therapeutics said late Thursday it has priced its initial public offering of about 6.9 million class A common shares at $16 per share for expected gross proceeds of $110 million.

Underwriters have been granted a 30-day option to purchase up to about 1 million additional common shares, the biopharmaceutical firm said.

Shares are expected to debut on the Nasdaq Global Select Market this Friday under the ticker symbol, "CTNM." The IPO is set to close on April 9, subject to customary closing conditions.